Pacific Edge Limited (ASX:PEB)

Australia flag Australia · Delayed Price · Currency is AUD
0.2200
0.00 (0.00%)
Jun 2, 2026, 10:42 AM AEST
Market Cap273.31M +323.9%
Revenue (ttm)10.83M -44.9%
Net Income-29.79M
EPS-0.03
Shares Out n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,306
Open0.2200
Previous Close0.2200
Day's Range0.2200 - 0.2200
52-Week Range0.0800 - 0.2500
Beta0.74
Analystsn/a
Price Targetn/a
Earnings DateMay 24, 2026

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva... [Read more]

Sector Healthcare
Founded 2001
Employees 114
Stock Exchange Australian Securities Exchange
Ticker Symbol PEB

Financial Performance

In fiscal year 2026, Pacific Edge's revenue was 13.60 million, a decrease of -40.22% compared to the previous year's 22.75 million. Losses were -35.78 million, 19.5% more than in 2025.

Financial numbers in NZD Financial Statements

News

Pacific Edge Earnings Call Transcript: H2 2026

FY 2026 saw revenue fall 47% and a net loss of NZD 35.8 million due to Medicare non-coverage, but recent draft Medicare coverage for Triage and Triage Plus, a successful NZD 25.4 million capital raise, and APAC growth position the business for recovery and future profitability.

8 days ago - Transcripts

Pacific Edge Slides: H2 2026

Pacific Edge has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 24, 2026.

8 days ago - Filings

Pacific Edge Earnings release: H2 2026

Pacific Edge released its H2 2026 earnings on May 24, 2026, summarizing the period's financial results.

8 days ago - Filings

Pacific Edge Annual report: H2 2026

Pacific Edge has published its H2 2026 annual report on May 24, 2026.

8 days ago - Filings

Fisher & Paykel downgrade drags NZX 50 lower as Pacific Edge jumps – Market close

Cancer tester Pacific Edge soared more than 54% on a key US Medicare draft ruling.

17 days ago - NZ Herald

Pacific Edge Transcript: Investor update

Draft Medicare coverage for key tests is expected before September 2026, with claim-by-claim reimbursement targeted to drive interim revenue. Cash burn has been reduced, a NZD 24 million capital raise is underway, and commercial payer adoption is advancing, supported by strong clinical evidence and new pilot studies.

22 days ago - Transcripts

Pacific Edge Slides: Investor update

Pacific Edge has posted slides in relation to its latest quarterly earnings report, which was published on May 10, 2026.

22 days ago - Filings

Pacific Edge Press release: Investor update

Pacific Edge issued a press release on May 10, 2026, disclosing material business information to investors.

22 days ago - Filings

Pacific Edge Slides: Investor presentation

Pacific Edge has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.

24 days ago - Filings

Pacific Edge Earnings Call Transcript: H1 2026

Revenue and test volumes declined sharply due to Medicare non-coverage, resulting in a $19.1M net loss and increased reliance on cash reserves. Strategic milestones include a price increase for Triage Plus and a key policy review by Novitas in early 2026, with recovery dependent on appeal outcomes.

6 months ago - Transcripts

Pacific Edge Quarterly report: H1 2026

Pacific Edge has published its H1 2026 quarterly earnings report on November 24, 2025.

6 months ago - Filings

Pacific Edge Slides: H1 2026

Pacific Edge has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 24, 2025.

6 months ago - Filings

Pacific Edge Transcript: AGM 2025

The meeting highlighted strategic progress with AUA guideline inclusion and a successful capital raise, despite the significant challenge of losing Medicare coverage. The board emphasized governance, risk management, and a pivot to commercial payers, with all resolutions passed by strong shareholder support.

10 months ago - Transcripts

Pacific Edge Slides: FY 2025

Pacific Edge has posted slides in relation to its FY 2025 quarterly earnings report, which was published on August 5, 2025.

10 months ago - Filings